( -- Data from Picoplatin Phase 1 Colorec...)Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting,Health

SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that data from a Phase 2 trial of picoplatin, the Company's lead product candidate, in patients with small cell lung cancer (SCLC) will be presented in a poster session at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago. Details are as follows:

    -- Abstract #7722, Poster #EE3

       A Phase 2 study of picoplatin as second-line therapy for patients with

       small cell lung cancer who have resistant or refractory disease or have

       relapsed within 180 days of completing first-line, platinum-containing

       chemotherapy.

       Bentzion D, Lipatov O, Poliakov I, MacKintosh R, Eckardt J, Breitz H.

       General Poster Session: Sunday, June 3, 8:00 a.m. to 12 p.m. Central

       time S Hall A2

In addition, two picoplatin abstracts have been selected for publication in the 2007 ASCO Proceedings and will be available online through http://asco.org. These abstracts include safety data from an ongoing Phase 1/2 study of picoplatin for the potential front-line treatment of colorectal cancer and from an ongoing Phase 1/2 study of picoplatin and docetaxel (Taxotere(R)) in chemotherapy-naive patients with metastatic hormone-refractory prostate cancer. Details are as follows:

    -- Abstract #14510

       Phase 1 study of picoplatin in combination with 5-fluorouracil and

       leucovorin as initial therapy in subjects with metastatic colorectal

       cancer.

       Gladkov Jr O, Manikhas G, Biakhov M, Tjulandin S, Karlin D.


    -- Abstract #15546

       Phase 1 study of picoplatin and doc
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim
Safety Analysis of Phase 1 Combination Trials of Picoplatin in
Colorectal and Prostate Cancers
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib
Combination Studies